A 38 h interval between hCG priming and oocyte retrieval increases in vivo and in vitro oocyte maturation rate in programmed IVM cycles

Author: Son Weon-Young   Chung Jin-Tae   Chian Ri-Cheng   Herrero Belen   Demirtas Ezgi   Elizur Shai   Gidoni Yariv   Sylvestre Camille   Dean Nicola   Tan Seang Lin  

Publisher: Oxford University Press

ISSN: 1460-2350

Source: Human Reproduction, Vol.23, Iss.9, 2008-09, pp. : 2010-2016

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

BACKGROUND Our aim was to evaluate whether extending the interval between human chorionic gonadotrophin (hCG) priming and immature oocyte retrieval increases the oocyte maturation rate following in vitro maturation (IVM). METHODS This study was performed retrospectively. IVM was performed on 113 polycystic ovary syndrome patients (n 120 cycles). Oocyte collection was performed either 35 h (Group 1; n 76) or 38 h (Group 2; n 44) after 10 000 IU of hCG priming. Following oocyte retrieval, oocyte maturity was assessed and the remaining immature oocytes were cultured in IVM medium up to Day 2. RESULTS The number of in vivo matured oocytes collected was significantly higher in Group 2 (13.6, 114/840 versus 7.3, 96/1312 in Group 1) (P < 0.01);="" the="" oocyte="" maturation="" rate="" after="" day="" 1="" was="" significantly="" higher="">P < 0.01)="" in="" group="" 2="" (46.3="" versus="" 36.0="" in="" group="" 1);="" and="" clinical="" pregnancy="" (40.9="" versus="" 25)="" and="" implantation="" rates="" (15.6="" versus="" 9.6)="" were="" better="" in="" group="" 2="" than="" those="" in="" group=""> CONCLUSIONS The results suggest that extending the period of hCG priming time from 35 to 38 h for immature oocyte retrieval promotes oocyte maturation in vivo and increases the IVM rate of immature oocytes. Therefore, oocyte retrieval after 38 h of hCG priming may improve subsequent pregnancy outcome in cycles programmed for IVM treatment.

Related content